![]() 2017), the first digital medicine released on the market is an antipsychotic. Although the DSM technology has been mostly tested in individuals with physical diseases (Frias et al. The DMS electronically confirms adherence to oral medication, acquires physiologic metrics periodically and remotely, and presents this information in a centralised manner. 2014).Ī novel medication adherence-assessment device, called digital medicine system (DMS), has recently been designed to assist health-care providers in objectively assessing patient adherence to prescribed medicines. By contrast, LAIs may notably simplify the daily routine of the patient, reduce the need of control by family members, and can ultimately ameliorate subjective attitude towards medications, and overall quality of life (Das et al. However, LAIs have been largely criticised for their limited flexibility in dosage control, the pain on the injection site and the culturally rooted idea of them as stigmatising and coercive drugs (Kirschner et al. ![]() Additionally, long-acting injectable antipsychotics (LAIs) are another frequently used approach to address non-adherence. 2005).Īmong the strategies that community psychiatric services can implement to reduce medication non-adherence in patients with severe mental disorders there are pill counts, electronic devices that capture pill container openings such as the Medication Event Monitoring System (MEMS), bottle caps, pharmacy refill records, mobile phone text reminders, psychosocial interventions such as ‘adherence therapy’, and even financial reinforces (Nieuwlaat et al. It is worth noting that, among other factors, medication non-adherence is a relevant predictor of relapse (Chen et al. ![]() Indeed, it has been estimated that only one out of three patients with schizophrenia is fully adherent to antipsychotic treatment and that at least 50% of patients are not fully adherent with their medications at some time during the treatment (Marder, 2003). Among people with severe mental disorders, those suffering from schizophrenia and bipolar disorder have particularly high levels of non-adherence, which contributes to the high burden of disability. Improving adherence to prescribed medicines is key in healthcare, as recently emphasised by the World Health Organization (WHO, 2003).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |